- Home
- BLX vs VRDN Comparison
BLX vs VRDN Comparison
Compare BLX & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLX
- VRDN
- Stock Information
- Founded
- BLX 1977
- VRDN 2006
- Country
- BLX Panama
- VRDN United States
- Employees
- BLX N/A
- VRDN N/A
- Industry
- BLX Commercial Banks
- VRDN Medical Specialities
- Sector
- BLX Finance
- VRDN Health Care
- Exchange
- BLX Nasdaq
- VRDN Nasdaq
- Market Cap
- BLX 1.4B
- VRDN 1.6B
- IPO Year
- BLX N/A
- VRDN N/A
- Fundamental
- Price
- BLX $38.30
- VRDN $13.51
- Analyst Decision
- BLX
- VRDN Buy
- Analyst Count
- BLX 0
- VRDN 12
- Target Price
- BLX N/A
- VRDN $36.44
- AVG Volume (30 Days)
- BLX 162.2K
- VRDN 1.1M
- Earning Date
- BLX 05-05-2025
- VRDN 05-07-2025
- Dividend Yield
- BLX 6.59%
- VRDN N/A
- EPS Growth
- BLX 23.03
- VRDN N/A
- EPS
- BLX 5.60
- VRDN N/A
- Revenue
- BLX $286,325,000.00
- VRDN $302,000.00
- Revenue This Year
- BLX $15.35
- VRDN N/A
- Revenue Next Year
- BLX $6.42
- VRDN $20,553.29
- P/E Ratio
- BLX $6.76
- VRDN N/A
- Revenue Growth
- BLX 19.98
- VRDN N/A
- 52 Week Low
- BLX $27.37
- VRDN $9.90
- 52 Week High
- BLX $42.88
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- BLX 56.22
- VRDN 49.64
- Support Level
- BLX $36.52
- VRDN $9.90
- Resistance Level
- BLX $38.34
- VRDN $14.22
- Average True Range (ATR)
- BLX 1.49
- VRDN 1.16
- MACD
- BLX 0.37
- VRDN 0.29
- Stochastic Oscillator
- BLX 88.56
- VRDN 76.65
About BLX Banco Latinoamericano de Comercio Exterior S.A.
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration across the region. The Bank provides foreign trade solutions to a select client base of premier Latin-American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments the Commercial Business Segment and the Treasury Business Segment.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.